Biological Activity
ABC 1183 (ABC1183) is a dual GSK-3/CDK9 inhibitor for cancer-cell proliferation and inflammatory signaling research. ABC1183 inhibited growth and decreased survival through G2/M arrest.
In Vitro
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Target and cell response | GSK3α/β and CDK9 inhibitor study; cancer-cell panel. [1] | ABC1183 inhibited growth and decreased survival through G2/M arrest. |
| Signaling changes | Glycogen synthase, β-catenin and MCL1 measurements. [1] | Treatment changed GSK3-associated phosphorylation and lowered MCL1 expression, connecting metabolic and transcriptional signaling. |
In Vivo
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Oral activity | Tumor and inflammation-driven gastrointestinal disease models. [1] | Oral administration reduced tumor growth and inflammatory symptoms, with lower TNFα and IL-6. |
| Tolerability boundary | Organ and hematologic observations in the reported animal experiments. [1] | The authors reported no toxicity in these assessments. Dose and observation-window details were not available in the verified abstract, so a general safety margin cannot be assigned. |
Interpretation
The reported lack of organ or hematological toxicity is limited to the study conditions.
